New strengths of Targinact

Napp has launched two new strengths of Targinact (oxycodone/naloxone). The 5mg/2.5mg and 40mg/20mg tablets provide greater dosing flexibility.

The starting dose remains 10mg/5mg, but the new lower-strength tablet allows a more gradual and individually tailored approach to dose titration. The new higher-strength preparation reduces tablet burden for patients requiring the maximum dose.

Furthermore, Targinact is now licensed for use at doses up to a maximum of 80mg oxycodone hydrochloride/40mg naloxone hydrochloride daily.

View Targinact drug record

Further information: Napp

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

First oral GLP-1 agonist launched for type II diabetes

First oral GLP-1 agonist launched for type II diabetes

Prescribers can now consider a GLP-1 agonist as an...

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Don't prescribe analgesics for chronic pain, new NICE guidance advises

Don't prescribe analgesics for chronic pain, new NICE guidance advises

Draft NICE guidance on chronic pain warns that prescribing...